Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 10 studies | 27% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 4616.14 | 578 / 578 | 99% | 21.76 | 1141 / 1155 |
thymus | 94% | 1439.01 | 612 / 653 | 99% | 25.49 | 599 / 605 |
adrenal gland | 100% | 2864.38 | 258 / 258 | 90% | 12.54 | 207 / 230 |
pancreas | 89% | 1210.68 | 293 / 328 | 95% | 22.86 | 169 / 178 |
esophagus | 84% | 3183.47 | 1209 / 1445 | 97% | 18.50 | 178 / 183 |
prostate | 95% | 2093.46 | 232 / 245 | 85% | 7.38 | 429 / 502 |
stomach | 88% | 1419.44 | 316 / 359 | 85% | 10.58 | 243 / 286 |
bladder | 76% | 1783.29 | 16 / 21 | 95% | 15.57 | 477 / 504 |
breast | 72% | 991.66 | 332 / 459 | 95% | 14.23 | 1064 / 1118 |
liver | 95% | 1614.04 | 215 / 226 | 71% | 6.49 | 289 / 406 |
uterus | 56% | 622.69 | 96 / 170 | 93% | 19.34 | 428 / 459 |
skin | 72% | 3547.08 | 1308 / 1809 | 77% | 11.61 | 364 / 472 |
intestine | 59% | 1426.65 | 573 / 966 | 81% | 9.10 | 427 / 527 |
kidney | 46% | 653.93 | 41 / 89 | 82% | 11.06 | 738 / 901 |
ovary | 45% | 507.31 | 81 / 180 | 80% | 8.51 | 343 / 430 |
brain | 36% | 431.44 | 938 / 2642 | 72% | 5.54 | 507 / 705 |
lymph node | 0% | 0 | 0 / 0 | 100% | 65.60 | 29 / 29 |
peripheral blood | 100% | 13446.50 | 929 / 929 | 0% | 0 | 0 / 0 |
spleen | 100% | 11603.42 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 7.43 | 1 / 1 |
tonsil | 0% | 0 | 0 / 0 | 98% | 33.89 | 44 / 45 |
adipose | 82% | 1167.36 | 991 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 80% | 1049.87 | 1062 / 1335 | 0% | 0 | 0 / 0 |
heart | 56% | 922.13 | 478 / 861 | 0% | 0 | 0 / 0 |
muscle | 46% | 1275.38 | 368 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 14% | 0.96 | 11 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007165 | Biological process | signal transduction |
GO_0006915 | Biological process | apoptotic process |
GO_0031398 | Biological process | positive regulation of protein ubiquitination |
GO_1900180 | Biological process | regulation of protein localization to nucleus |
GO_0050672 | Biological process | negative regulation of lymphocyte proliferation |
GO_0046651 | Biological process | lymphocyte proliferation |
GO_0005874 | Cellular component | microtubule |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
Gene name | RASSF5 |
Protein name | FLJ00186 protein (Ras association domain family member 5) Ras association domain-containing protein 5 (New ras effector 1) (Regulator for cell adhesion and polarization enriched in lymphoid tissues) (RAPL) Ras association domain family member 5 |
Synonyms | NORE1 FLJ00186 RAPL |
Description | FUNCTION: Potential tumor suppressor. Seems to be involved in lymphocyte adhesion by linking RAP1A activation upon T-cell receptor or chemokine stimulation to integrin activation. Isoform 2 stimulates lymphocyte polarization and the patch-like distribution of ITGAL/LFA-1, resulting in an enhanced adhesion to ICAM1. Together with RAP1A may participate in regulation of microtubule growth. The association of isoform 2 with activated RAP1A is required for directional movement of endothelial cells during wound healing. May be involved in regulation of Ras apoptotic function. The RASSF5-STK4/MST1 complex may mediate HRAS and KRAS induced apoptosis. . |
Accessions | ENST00000579436.7 [Q8WWW0-1] Q8WWW0 ENST00000581503.6 ENST00000577571.5 [Q8WWW0-2] ENST00000636182.1 ENST00000581888.1 A0A075B763 A0A1B0GTG4 Q8TEK8 ENST00000580449.5 [Q8WWW0-3] |